BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price, Quote, News and Overview
NASDAQ:BDTX - Nasdaq - US09203E1055 - Common Stock
BDTX Quote and Key Statistics
BLACK DIAMOND THERAPEUTICS I
NASDAQ:BDTX (1/21/2025, 8:00:00 PM)
Premarket: 2.19 -0.05 (-2.23%)2.24
+0.04 (+1.82%)
BDTX Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.01% | ||
| ROE | -75.03% | ||
| Debt/Equity | 0 |
BDTX Performance and Technical Analysis
BDTX Ownership and Analysts
BDTX Latest News and Analysis
Gapping stocks in Monday's session
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S...
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing...
About BDTX
Company Profile
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The firm is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The firm is also focused on a development candidate against an undisclosed, validated oncogene.
Company Info
BLACK DIAMOND THERAPEUTICS I
One Main Street, 14th Floor
Cambridge MASSACHUSETTS 02142 US
CEO: David M. Epstein
Employees: 54
Company Website: https://www.blackdiamondtherapeutics.com/
Investor Relations: https://investors.blackdiamondtherapeutics.com/
Phone: 16174175868
BDTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |